Exelixis Inc (EXEL)

8.71
0.03 0.35
NASDAQ : Health Care
Prev Close 8.68
Open 8.68
Day Low/High 8.61 / 8.76
52 Wk Low/High 3.55 / 8.74
Volume 2.73M
Avg Volume 6.28M
Exchange NASDAQ
Shares Outstanding 228.74M
Market Cap 1.96B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

'Mad Money' Lightning Round: I'm Sticking With Wells Fargo

'Mad Money' Lightning Round: I'm Sticking With Wells Fargo

Cramer is taking Honeywell over Boeing and is nervous about AIG.

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Jim Cramer's 'Mad Money' Recap: We've Seen This 'Brexit' Movie Before

Sure, we're in a bad moment but is it really worth ditching high-quality stocks to run for the hills? Cramer asks.

Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Exelixis (EXEL) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate

Today's Perilous Reversal Stock: Exelixis (EXEL)

Today's Perilous Reversal Stock: Exelixis (EXEL)

Trade-Ideas LLC identified Exelixis (EXEL) as a "perilous reversal" (up big yesterday but down big today) candidate

Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment

Exelixis (EXEL) Stock Gains on Positive Trial Results for Kidney Cancer Treatment

Exelixis (EXEL) stock is higher in pre-market trading on Monday after the company announced positive trial data for its treatment for advanced kidney cancer.

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Regulatory News: Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of positive data from subgroup analyses of the pivotal METEOR trial comparing CABOMETYX™...

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis And Its Partner Ipsen Announce Positive Overall Survival Results From Subgroup Analyses Of Phase 3 Trial Of CABOMETYX™ (cabozantinib) Tablets In Advanced Renal Cell Carcinoma At 2016 ASCO Annual Meeting

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of positive data from subgroup analyses of the pivotal METEOR trial comparing CABOMETYX™ (cabozantinib) tablets with...

Exelixis And Its Partner Ipsen Announce Phase 3 Trial Results Of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit For Previously Treated Patients With Advanced Renal Cell Carcinoma Presented At ASCO

Exelixis And Its Partner Ipsen Announce Phase 3 Trial Results Of CABOMETYX™ (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit For Previously Treated Patients With Advanced Renal Cell Carcinoma Presented At ASCO

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced overall survival (OS) results from the phase 3 METEOR trial of CABOMETYX™ (cabozantinib) tablets in patients with advanced renal cell...

Exelixis Announces Genentech Presentation Of Preliminary Phase 1B Trial Results For The Combination Of Cobimetinib And Atezolizumab At ASCO 2016 Annual Meeting

Exelixis Announces Genentech Presentation Of Preliminary Phase 1B Trial Results For The Combination Of Cobimetinib And Atezolizumab At ASCO 2016 Annual Meeting

Exelixis, Inc. (NASDAQ:EXEL) today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of...

Strong On High Volume: Exelixis (EXEL)

Strong On High Volume: Exelixis (EXEL)

Trade-Ideas LLC identified Exelixis (EXEL) as a strong on high relative volume candidate

Exelixis Announces Results From Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis Announces Results From Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC).

Exelixis (EXEL) Showing Signs Of Perilous Reversal Today

Exelixis (EXEL) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified Exelixis (EXEL) as a "perilous reversal" (up big yesterday but down big today) candidate

Exelixis To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 10

Exelixis To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference On May 10

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Announces First Quarter 2016 Financial Results And Provides Corporate Update

Exelixis Announces First Quarter 2016 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2016 and provided an update on progress toward delivering upon its key 2016 corporate objectives and clinical development milestones.

Exelixis To Release First Quarter 2016 Financial Results On Wednesday, May 4, 2016

Exelixis To Release First Quarter 2016 Financial Results On Wednesday, May 4, 2016

Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2016 financial results will be released on Wednesday, May 4, 2016 after the markets close.

CABOMETYX™ 60 Mg Tablets

CABOMETYX™ 60 Mg Tablets

Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.

Exelixis-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting

Exelixis-Discovered Compounds To Be Featured In 18 Presentations At 2016 ASCO Annual Meeting

Exelixis, Inc. (NASDAQ: EXEL) today announced that new data for cabozantinib, cobimetinib and XL888 will be presented at the upcoming 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June...

Exelixis (EXEL) Stock Climbs, Stifel Upgrades

Exelixis (EXEL) Stock Climbs, Stifel Upgrades

Exelixis (EXEL) stock is rising Monday as Stifel upgraded the stock to ‘buy’ from ‘hold.’

Exelixis To Present At Two Investor Conferences In March

Exelixis To Present At Two Investor Conferences In March

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis (EXEL) Stock Climbs on Q4 Results

Exelixis (EXEL) Stock Climbs on Q4 Results

Exelixis (EXEL) stock is jumping on Tuesday after the company reported its 2015 fourth quarter results after yesterday’s market close.

Exelixis Announces Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update

Exelixis Announces Fourth Quarter And Full Year 2015 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year of 2015 and provided an overview of key 2016 corporate objectives and clinical development milestones.

Exelixis And Ipsen Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Regions Outside The United States, Canada And Japan

Exelixis And Ipsen Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Regions Outside The United States, Canada And Japan

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib, Exelixis' lead oncology drug.

Exelixis To Release Fourth Quarter And Full Year 2015 Financial Results On Monday, February 29, 2016

Exelixis To Release Fourth Quarter And Full Year 2015 Financial Results On Monday, February 29, 2016

Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2015 financial results will be released on Monday, February 29, 2016 after the markets close.

Exelixis To Present At The Leerink Partners 5th Annual Global Healthcare Conference On February 10

Exelixis To Present At The Leerink Partners 5th Annual Global Healthcare Conference On February 10

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question

Exelixis Kidney Cancer Survival Benefit Doesn't Address Competitive Question

Exelixis didn't provide specifics about the duration of Cometriq's survival benefit, so it's not known if the new data will help the company compete any better against Bristol-Myers Squibb.

Exelixis Announces Positive Overall Survival Results From METEOR, The Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma

Exelixis Announces Positive Overall Survival Results From METEOR, The Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced positive overall survival (OS) results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with advanced renal cell carcinoma (RCC) who...

Exelixis Announces European Medicines Agency Acceptance Of Marketing Authorization Application For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma

Exelixis Announces European Medicines Agency Acceptance Of Marketing Authorization Application For Cabozantinib As A Treatment For Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for cabozantinib as a treatment for patients with advanced renal cell...